{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-188839","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2023-07-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.075746+00:00","generated_at":"2026-06-13T06:48:32.844904+00:00","sec_items":["1.01","2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Acadia expands trofinetide rights globally; Q2 DAYBUE net sales $21-23M","bullets":["Acadia pays Neuren $100M upfront for ex-North American trofinetide rights and global NNZ-2591 rights in Rett/Fragile X.","Potential milestone payments up to $405M each for trofinetide and NNZ-2591 in North America; additional milestones outside NA.","Preliminary Q2 2023 DAYBUE net sales $21-23M; Q3 guidance $45-55M.","NUPLAZID Q2 preliminary net sales $140-144M; full year 2023 guidance $530-545M.","Acadia to submit NDS for trofinetide in Canada within 18 months; plans for Europe, Asia later."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-188839","json":"https://secwatch.observer/filing/0001193125-23-188839.json","markdown":"https://secwatch.observer/filing/0001193125-23-188839.md","text":"https://secwatch.observer/filing/0001193125-23-188839.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000119312523188839/0001193125-23-188839-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000119312523188839/d533087d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T06:48:32.844904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"87f5b4804f89620c137bb10a7a6b520acc6cf276","claim":"ACADIA PHARMACEUTICALS INC reported second quarter of 2023 results: revenue $140 to $144 million. Guidance reaffirmed.","evidence_excerpt":"DAYBUE 2Q 2023 preliminary net sales: $21 to $23 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070494/000119312523188839/0001193125-23-188839-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter of 2023"},{"label":"Revenue","value":"$140 to $144 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"87f5b4804f89620c137bb10a7a6b520acc6cf276","claim":"ACADIA PHARMACEUTICALS INC reported second quarter of 2023 results: revenue $140 to $144 million. Guidance reaffirmed.","evidence_excerpt":"NUPLAZID 2Q 2023 preliminary net sales: $140 to $144 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070494/000119312523188839/0001193125-23-188839-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter of 2023"},{"label":"Revenue","value":"$140 to $144 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"dce99021c0f52e97cdea26f99d4173c0edd485da","claim":"ACADIA PHARMACEUTICALS INC entered into Joint Venture and License Agreement with Neuren Pharmaceuticals Limited valued at upfront payment $100.0 million; milestone payments up to $405.0 million per product; tiered double-d (effective 2023-07-13).","evidence_excerpt":"On July 13, 2023, Acadia Pharmaceuticals Inc. (the “Company”) and Neuren Pharmaceuticals Limited (“Neuren”) entered into a joint venture and license agreement (the “License Agreement”) for the global commercialization and development of trofinetide and of Neuren’s development candidate NNZ-2591.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070494/000119312523188839/0001193125-23-188839-index.htm","confidence":0.99,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Neuren Pharmaceuticals Limited"},{"label":"Value","value":"upfront payment $100.0 million; milestone payments up to $405.0 million per product; tiered double-d"},{"label":"Effective","value":"2023-07-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}